These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29773827)

  • 1. Cardiac pacemaker channel (HCN4) inhibition and atrial arrhythmogenesis after releasing cardiac sympathetic activation.
    Chobanyan-Jürgens K; Heusser K; Duncker D; Veltmann C; May M; Mehling H; Luft FC; Schröder C; Jordan J; Tank J
    Sci Rep; 2018 May; 8(1):7748. PubMed ID: 29773827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using High-Fidelity Cardiovascular Phenotyping.
    Heusser K; Tank J; Brinkmann J; Schroeder C; May M; Großhennig A; Wenzel D; Diedrich A; Sweep FC; Mehling H; Luft FC; Jordan J
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26764413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study.
    Schroeder C; Heusser K; Zoerner AA; Großhennig A; Wenzel D; May M; Sweep FC; Mehling H; Luft FC; Tank J; Jordan J
    Clin Pharmacol Ther; 2014 Jun; 95(6):601-7. PubMed ID: 24509430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine prevents deleterious effects of dopamine therapy in heart failure: No role for HCN4 overexpression.
    Paterek A; Sochanowicz B; Oknińska M; Śmigielski W; Kruszewski M; Mackiewicz U; Mączewski M; Leszek P
    Biomed Pharmacother; 2021 Apr; 136():111250. PubMed ID: 33450487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization-activated cyclic nucleotide gated channel overexpression.
    Wang J; Yang YM; Li Y; Zhu J; Lian H; Shao XH; Zhang H; Fu YC; Zhang LF
    J Cardiovasc Electrophysiol; 2019 Feb; 30(2):242-252. PubMed ID: 30302853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.
    Scheruebel S; Koyani CN; Hallström S; Lang P; Platzer D; Mächler H; Lohner K; Malle E; Zorn-Pauly K; Pelzmann B
    J Mol Cell Cardiol; 2014 Jul; 72(100):64-73. PubMed ID: 24583250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine augments high-frequency dynamic gain of the heart rate response to low- and moderate-intensity vagal nerve stimulation under β-blockade.
    Kawada T; Yamamoto H; Uemura K; Hayama Y; Nishikawa T; Zheng C; Li M; Miyamoto T; Sugimachi M
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2201-H2210. PubMed ID: 33891515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: A preliminary report.
    Núñez L; Crespo-Leiro MG; Marrón-Liñares GM; Suarez-Fuentetaja N; Barge-Caballero E; Paniagua-Martín MJ; Marzoa-Rivas R; Grille-Cancela Z; Muñiz-García J; Vazquez-Rodriguez JM; Hermida-Prieto M
    Cardiol J; 2016; 23(5):573-582. PubMed ID: 27439367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetic model of ivabradine recapitulates results from randomized clinical trials.
    Legault MA; Sandoval J; Provost S; Barhdadi A; Lemieux Perreault LP; Shah S; Lumbers RT; de Denus S; Tyl B; Tardif JC; Dubé MP
    PLoS One; 2020; 15(7):e0236193. PubMed ID: 32692755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural determinants of ivabradine block of the open pore of HCN4.
    Saponaro A; Krumbach JH; Chaves-Sanjuan A; Sharifzadeh AS; Porro A; Castelli R; Hamacher K; Bolognesi M; DiFrancesco D; Clarke OB; Thiel G; Moroni A
    Proc Natl Acad Sci U S A; 2024 Jul; 121(27):e2402259121. PubMed ID: 38917012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cohesin-protein Shugoshin-1 controls cardiac automaticity via HCN4 pacemaker channel.
    Liu D; Song AT; Qi X; van Vliet PP; Xiao J; Xiong F; Andelfinger G; Nattel S
    Nat Commun; 2021 May; 12(1):2551. PubMed ID: 33953173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.
    Bucchi A; Tognati A; Milanesi R; Baruscotti M; DiFrancesco D
    J Physiol; 2006 Apr; 572(Pt 2):335-46. PubMed ID: 16484306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets.
    Koncz I; Szél T; Jaeger K; Baczkó I; Cerbai E; Romanelli MN; Gy Papp J; Varró A
    Curr Med Chem; 2011; 18(24):3662-74. PubMed ID: 21774761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels.
    Haechl N; Ebner J; Hilber K; Todt H; Koenig X
    Cell Physiol Biochem; 2019; 53(1):36-48. PubMed ID: 31169990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PP2 prevents isoproterenol stimulation of cardiac pacemaker activity.
    Huang J; Lin YC; Hileman S; Martin KH; Hull R; Yu HG
    J Cardiovasc Pharmacol; 2015 Feb; 65(2):193-202. PubMed ID: 25658311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific inhibition of HCN channels slows rhythm differently in atria, ventricle and outflow tract and stabilizes conduction in the anoxic-reoxygenated embryonic heart model.
    Sarre A; Pedretti S; Gardier S; Raddatz E
    Pharmacol Res; 2010 Jan; 61(1):85-91. PubMed ID: 19818405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel HCN4 Blockers with Unique Blocking Kinetics and Binding Properties.
    Nakashima K; Nakao K; Matsui H
    SLAS Discov; 2021 Aug; 26(7):896-908. PubMed ID: 34041946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac arrhythmia induced by genetic silencing of 'funny' (f) channels is rescued by GIRK4 inactivation.
    Mesirca P; Alig J; Torrente AG; Müller JC; Marger L; Rollin A; Marquilly C; Vincent A; Dubel S; Bidaud I; Fernandez A; Seniuk A; Engeland B; Singh J; Miquerol L; Ehmke H; Eschenhagen T; Nargeot J; Wickman K; Isbrandt D; Mangoni ME
    Nat Commun; 2014 Aug; 5():4664. PubMed ID: 25144323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivabradine for the Treatment of Cardiovascular Diseases.
    Ide T; Ohtani K; Higo T; Tanaka M; Kawasaki Y; Tsutsui H
    Circ J; 2019 Jan; 83(2):252-260. PubMed ID: 30606942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology.
    Sartiani L; Romanelli MN; Mugelli A; Cerbai E
    Curr Drug Targets; 2015; 16(8):868-76. PubMed ID: 26028050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.